From basic science, new therapeutic targets were shown including the E2‐MuRF1 interaction, gp130 muscle signalling, miRNA‐26a, the interleukin signalling, the activation of the AP‐1 family of transcription factors mitogen‐activated protein kinases, the ubiquitin specific protease 19, MCP‐1 together with GDF 15, and the influence and the role of the gut microbiota in the therapeutic management of muscle wasting and cachexia. The gene discussed is CCL2; the disease is Cachexia.